Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comcast Corporation (CMCSA) vs Danaher Corporation (DHR) Price & Performance

Comcast CorporationTrade
Danaher CorporationTrade

Price performance (Past 24H)

Key statistics

Comcast Corporation vs Danaher Corporation — how do they compare? Comcast Corporation trades at $25.52 (market cap $91.02B), while Danaher Corporation trades at $206.7 (market cap $145.83B). The key difference: Danaher Corporation is the larger of the two by market cap, and Comcast Corporation pays the higher dividend (5.15%). Which is the better fit depends on your goals.

CMCSADHR
Market Cap
$91.02B$145.83B
Sector
MediaHealth
52-Week High
$32.50$242.05
52-Week Low
$21.92$161.91
Enterprise Value
$173.74B$168.04B
Dividend Yield
5.15%0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comcast Corporation

Comcast (CMCSA) trades at $25.20, down 0.63% today, with strong fundamentals including a P/E of 8.22 and net income margin of 8.97%. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI indicates potential overbought conditions. Recent earnings beats and a planned NBCUniversal spinoff provide positive catalysts, while analyst consensus remains strongly bullish with a $27.78 price target.

CMCSA presents compelling value with discounted valuation multiples and consistent cash flow generation. Key opportunities include wireless growth and media separation, while risks involve competitive pressures and potential economic headwinds affecting consumer spending. The stock offers a balanced risk-reward profile for long-term investors seeking stable returns.

Danaher Corporation

Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.

The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.

Read more on CMCSA

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR